Enlivex Therapeutics Ltd Market Cap ($126.77K)
Market Cap & Net Worth: Enlivex Therapeutics Ltd (ENLV)
Enlivex Therapeutics Ltd market cap. Enlivex Therapeutics Ltd (TA:ENLV) has a market capitalization of $126.77K (ILA47.29 Million) as of October 30, 2026. Listed on the TA stock exchange, this Israel-based company holds position #31469 globally and #462 in its home market, demonstrating a -85.24% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Enlivex Therapeutics Ltd's stock price ILA0.20 by its total outstanding shares 237381498 (237.38 Million).
Enlivex Therapeutics Ltd Market Cap History (2019–2026)
Enlivex Therapeutics Ltd market cap history from 2019 to 2026. Data shows change from $1.88 Billion to $126.77K (-77.52% CAGR). Check today's stock price for Enlivex Therapeutics Ltd for real-time trading data and today's change.
Enlivex Therapeutics Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Enlivex Therapeutics Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see ENLV cash flow conversion for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ENLV by Market Capitalization
Companies near Enlivex Therapeutics Ltd in the global market cap rankings as of October 30, 2026. See how leveraged is Enlivex Therapeutics Ltd's balance sheet to understand what proportion of total assets are financed by equity.
Key companies related to Enlivex Therapeutics Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #419 globally with a market cap of $67.66 Billion USD ( AU$95.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #500 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $529.69 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $813.27 |
| #419 | CSL Ltd | AU:CSL | $67.66 Billion | AU$197.10 |
| #500 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $214.17 |
Market Capitalization of Enlivex Therapeutics Ltd (2019–2026)
Market capitalization of Enlivex Therapeutics Ltd from 2019 to today. Between 2019 and today, Enlivex Therapeutics Ltd's market cap moved from $1.88 Billion to $ 126.77K, with a yearly change of -77.52%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ILA126.77K | -99.91% |
| 2025 | ILA136.32 Million | -48.20% |
| 2024 | ILA263.16 Million | -57.46% |
| 2023 | ILA618.59 Million | -27.68% |
| 2022 | ILA855.34 Million | -24.92% |
| 2021 | ILA1.14 Billion | -36.97% |
| 2020 | ILA1.81 Billion | -3.79% |
| 2019 | ILA1.88 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 29th, 2026 the market cap of Enlivex Therapeutics Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $126.77K USD |
| MoneyControl | $126.77K USD |
| MarketWatch | $126.77K USD |
| marketcap.company | $126.77K USD |
| Reuters | $126.77K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Enlivex Therapeutics Ltd
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee o… Read more